Kezar Life Sciences Inc. $561.261M Market Capitalization Between 2020 and 2021, year-over-year (YoY) funding in the biotech market increased by an impressive 39.6%. Currently, some of the biggest trends…
biotechnology stocks
Closing the Diabetic Loop Before we get into this week’s sector roundup, let’s talk about diabetes. I am a sucker for sweets, so much so that I was diagnosed…
A Pain in the Behind I don’t fear a lot of things. Well, other than spiders, heights, and being stabbed. However, more than anything I have always been afraid…
Forget-Me-Not Whether you believe in the metaphysical or not, there’s no denying the achievements of science. In particular, biotechnology has uncovered significant advancements in the field of medicine. For context,…
Old Memories I have always been a sucker for nostalgia. When I first started writing for Equity Guru, I spent most of my time covering biotechnology companies. Whether they…
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million…